Potential Gains and Defined Risk Could Make This Trade Appealing
 | You're receiving this email because you are subscribed to Options Profits Daily,
if you no longer wish to receive these emails you can unsubscribe here. | |  | |
 | | Potential Gains and Defined Risk Could Make This Trade Appealing | | | The technology could be life changing. The news report noted that the China National Medical Products Administration (NMPA) approved the New Drug Application (NDA) for ZEJULA (niraparib), an oral, once-daily poly (ADP-ribose) polymerase (PARP) inhibitor as maintenance therapy.
This drug will be used to treat adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, who are in a complete or partial response to platinum-based chemotherapy.
In china, ovarian cancer is one of the most common gynecologic cancers in China with more than 52,000 newly diagnosed cases and 23,000 deaths in China each year. The 5-year overall survival rate of ovarian cancer patients is 46% across all stages, but only 29% in patients diagnosed with distant metastatic disease.
The benefits of the technology might affect thousands of lives and the trading opportunities associated with the technology is available now. We found one potential opportunity and, as we explain in our latest article, this trade could deliver a gain of 127%.
That potential gain is determined with actual market data and the risks can also be defined precisely with recent market data. We also explain the strategy and share the news which helped us to identify the opportunity. All of this detail, and the math of the trade, could help you identify similar opportunities in biotech or any other market sector since these opportunities really do exist, as we explain.
We have all the details in our latest free educational article that is available right here.
| | YOU PROBABLY MISSED THIS: |  | | | | ` | |
Not sure the best way to get started?
Follow these simple steps to hit the ground running. | |
Nothing in this email should be considered personalized financial advice. ALWAYS DO YOUR OWN RESEARCH and consult with a licensed investment professional before making an investment. This communication should not be used as a basis for making any investment.
By reading this communication, you agree to the terms of this disclaimer, including, but not limited to: releasing The Company, its affiliates, assigns and successors from any and all liability, damages, and injury from the information contained in this communication. You further warrant that you are solely responsible for any financial outcome that may come from your investment decisions.
As defined in the United States Securities Act of 1933 Section 27(a), as amended in the Securities Exchange Act of 1934 Section 21(e), statements in this communication which are not purely historical are forward-looking statements and include statements regarding beliefs, plans, intent, predictions or other statements of future tense.
Investing is inherently risky. While a potential for rewards exists, by investing, you are putting yourself at risk. You must be aware of the risks and be willing to accept them in order to invest in any type of security. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell securities. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.
| | |
No comments:
Post a Comment